Raxibacumab is a monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate. Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin.
- Mechanism
- Curator reviewed
Raxibacumab is a monoclonal antibody that binds free PA with an affinity equilibrium dissociation constant (Kd) of 2.78 ± 0.9 nM. Raxibacumab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and edema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin. It does not have direct antibacterial activity.
- Primary indication
- Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not...Curator reviewed · 2 structured indications
- Formula / weight
- C6320H9794N1702O1998S42 · 142844.5367 Da
- First approval
- United States, 2012
- Also known as
- PA mAb
Resolves to
What you can answer from here — as of February 11, 2026
Which drugs share a target with Raxibacumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account